T. Crockett
Gründer bei KalVista Pharmaceuticals Ltd.
Vermögen: 2 Mio $ am 30.04.2024
Aktive Positionen von T. Crockett
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Direktor/Vorstandsmitglied | 01.04.2010 | - |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Direktor/Vorstandsmitglied | 01.01.2011 | - |
Vorstandsvorsitzender | 01.01.2011 | - | |
Gründer | 01.01.2011 | - |
Karriereverlauf von T. Crockett
Ehemalige bekannte Positionen von T. Crockett
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
KALVISTA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 21.11.2016 | 06.03.2024 |
Vorstandsvorsitzender | 21.11.2016 | 06.03.2024 | |
Gründer | 26.03.2004 | 06.03.2024 | |
ZARS Pharma, Inc.
ZARS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZARS Pharma, Inc. develops and distributes drugs. It is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs, primarily for the treatment of pain, using its proprietary drug delivery technologies. The company was founded by Jie Zhang, Theodore H. Stanley, Larry D. Rigby and Michael A. Ashburn in 1996 and is headquartered in Salt Lake City, UT. | Corporate Officer/Principal | 01.08.1999 | - |
Ausbildung von T. Crockett
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Harvard Business School | Undergraduate Degree |
University of Utah | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Vereinigtes Königreich | 3 |
Operativ
Director/Board Member | 3 |
Chief Executive Officer | 2 |
Founder | 2 |
Sektoral
Health Technology | 4 |
Consumer Services | 4 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
KALVISTA PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
ZARS Pharma, Inc.
ZARS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZARS Pharma, Inc. develops and distributes drugs. It is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs, primarily for the treatment of pain, using its proprietary drug delivery technologies. The company was founded by Jie Zhang, Theodore H. Stanley, Larry D. Rigby and Michael A. Ashburn in 1996 and is headquartered in Salt Lake City, UT. | Health Technology |
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Commercial Services |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Health Technology |
- Börse
- Insiders
- T. Crockett
- Erfahrung